An Open-Label, Non-Inferiority Study Evaluating the Efficacy and Safety of Two Injection Schedules of Xeomin® (incobotulinumtoxinA) [Short Flex vs. Long Flex] in Subjects with Cervical Dystonia < 10 Weeks of Benefit from OnabotulinumtoxinA Treatment

Clinical Trial Investigator Name: Cindy Zadikoff, MD

Aim: This study will compare Xeomin®, a botulinum toxin treatment, in shorter treatment intervals (Short Flex dosing) to the standard interval dosing (Long Flex dosing) in order to determine if more frequent dosing leads to development of botulinim toxin resistance (making treatment with botulinum toxin less effective).

Procedures: Patients will be asked to complete questionnaires during 12-17 clinic visits as well as questionnaires on either a daily or weekly basis to evaluate the efficacy of each course of injections.

Study duration: 12 -17 visits

Compensation: A stipend of $50 in cash will be given following completion of each study visit. If you complete the entire study, then you will receive a total of up to $600.


For More Information: Call us at (312) 503-0755, or email


Northwestern Medicine and Northwestern University Feinberg School of Medicine will not release any of your personal information to 3rd parties, participating organizations and/or other institutions. Your information will only be available to the researcher(s) after you indicate interest in being contacted about a particular study.

Newly Diagnosed

Newly diagnosed with Parkinson’s disease and not yet treated? Please complete the Northwestern Medicine Parkinson’s Disease and Movement Disorders Center online appointment form to discuss next steps.

Feinberg is not a site of care. PDMDC faculty see patients through our affiliated clinic.